10.3389/fpsyg.2012.00132

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Prematurity is a major cause of neonatal morbidity and mortality. Inflammatory imbalance is critical in preterm complications, and interleukin-6 (IL-6) plays a pivotal role in this dysregulation. Currently, there is no comprehensive review focusing specifically on IL-6 in the context of neonatal complications of prematurity. Thus, we review the involvement of IL-6 in various prematurity complications, exploring its mechanisms and clinical implications. We also discuss current and emerging therapies targeting IL-6, its receptor, and the trans-signaling pathway, focusing on the potential of these cytokines as therapeutic targets for the development of safe and effective treatments for neonatal complications of prematurity. However, while IL-6 shows consistent value as an early predictive biomarker, its translation into targeted therapy for preterm infants remains preliminary, with substantial gaps in safety and pharmacokinetic data that require further investigation.

Abstract: PubMed · Datensatz